We recently updated our Privacy Notice and Terms of Use.
Med-IQ
And the Beat Goes On: Clinical Implications and Real-World Application of Advances in Heart Failure
Med-IQ Express Med-IQ Express

And the Beat Goes On: Clinical Implications and Real-World Application of Advances in Heart Failure


Released:
7/14/17
Expires:
7/13/18

Maximum Credits:

0.25

Med-IQ Express Med-IQ Express
Released:
7/14/17

Expires:
7/13/18

Maximum Credits:
0.25
Med-IQ Express Med-IQ Express

Released:
7/14/17
Expires:
7/13/18


Maximum Credits:
0.25


Overview: This 15-minute publication begins with a brief video in which a clinical expert discusses guideline updates for the pharmacologic management of patients with chronic heart failure and reduced ejection fraction. The clinical trial data that led to these updated guidelines are further discussed in the publication.

CME Information:

Faculty
Akshay S. Desai, MD, MPH
Associate Professor
Harvard Medical School
Director, Heart Failure Disease Management
Division of Cardiovascular Medicine
Brigham and Women’s Hospital
Boston, MA
 
Activity Planners
Christie Avraamides, PhD
Clinical Content Manager
Med-IQ
Baltimore, MD
 
Stephanie Stowell Wenick, MPhil
Manager, Educational Strategy and Content
Med-IQ
Baltimore, MD
 
Laura Rafferty
Managing Editor
Med-IQ
Baltimore, MD
 
Amy Sison
Director of Continuing Medical Education
Med-IQ
Baltimore, MD

Learning Objectives
Upon completion, participants should be able to:

  • Apply current evidence-based guideline recommendations to treatment decisions for patients with chronic HF and reduced ejection fraction to reduce the risk of morbidity and mortality  
 
Target Audience
This activity is intended for cardiologists.
 
Series Overview/Statement of Need
In 2016, the American College of Cardiology, American Heart Association, and Heart Failure Society of America jointly published a focused update on the pharmacologic management of heart failure (HF) to provide guidance regarding the use of two new medical therapies approved by the US Food and Drug Administration for the treatment of HF and reduced ejection fraction. These updated guidelines recommend the use of sacubitril/valsartan over angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for select patients with HF with reduced ejection fraction. The guidelines also suggest the addition of ivabradine for additional heart rate control in patients with HF and reduced ejection fraction who maintain a heart rate of at least 70 bpm in sinus rhythm despite titration of beta blockers. Clinicians should familiarize themselves with the updated guidelines and current clinical trial data to provide optimal care to their patients.
 
Accreditation/Designation Statements
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Med-IQ designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
Medium/Method of Participation
This CME activity consists of a 0.25-credit online publication. To receive credit, read the introductory CME material, read the publication, and complete the post-survey, evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.
 
Initial Release Date: July 14, 2017
Expiration Date: July 13, 2018
Estimated Time to Complete This Activity: 15 minutes
 
Disclosure Policy
Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 12 months, including those of a spouse/life partner, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.
 
Disclosure Statement
The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation. 
 
Akshay S. Desai, MD, MPH
Consulting fees/advisory boards: AstraZeneca, Cheetah Medical, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Relypsa, Inc., Sanofi-aventis U.S. Inc.
Contracted research: Novartis Pharmaceuticals Corporation

The writer, peer reviewers, and activity planners have no financial relationships to disclose.

Statement of Evidence-Based Content
Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, it is the policy of Med-IQ to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.
 
Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity.

Contact Information       
For questions or comments about this activity, please contact Med-IQ.
Call (toll-free) 866 858 7434 or e-mail info@med-iq.com.
 
Hardware/Software Requirements
Operating System
Microsoft Windows® 8, Windows 7
Mac OS 10.7 (Lion) or newer

Browser
Microsoft Internet Explorer 8.0 or later
Mozilla Firefox - latest version
Download: http://www.mozilla.org/en-US/firefox/new/
 
Google Chrome - latest version
Download: http://www.google.com/chrome
 
Apple Safari - latest version
Download: http://www.apple.com/safari/download/

PDF Viewer
Adobe Acrobat Reader® or Adobe Reader
Download: http://get.adobe.com/reader/

Adobe Flash Player
Adobe Flash Player 9 or later
Download: http://get.adobe.com/flashplayer/ 
 
For technical support, go to http://www.med-iq.com/index.cfm?fuseaction=content.support.
 
ADA Statement
Med-IQ fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please contact Med-IQ at 443 543 5200.
 
Disclaimer
The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Privacy & Confidentiality
Med-IQ is committed to honoring your privacy and protecting any personal information you choose to share with us. For detailed information about our privacy notice, please visit: www.med-iq.com/privacy-statement/.
 
Acknowledgment of Commercial Support
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

Copyright
© 2017 Med-IQ®. All rights reserved.
 

Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.

Need help? If you need to speak with a member of our team, please call (toll-free) 866 858 7434 or email info@med-iq.com. For technical assistance, please refer to our support manual.